UNSPSC 51161524: Tiotropium

This classification denotes an antimuscarinic agent with the molecular formula C19H22NO4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0EB439235F, chemically known as 7-((hydroxybis(2-thienyl)acetyl)oxy)-9,9-dimethyl-3-oxa-9-azoniatricyclo(3.3.1.0(2,4))nonane bromide but generally known as tiotropium, which bears US NIH Compound Identifier 5487426. European Medicines Agency schedules Tiotropium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25691.

UNSPSC 51161524 Tiotropium is a Commodity code encompassing branded and generic inhalation maintenance medications for chronic obstructive pulmonary disease and asthma supplied through state and local government pharmaceutical procurement vehicles. State and local governments acquire tiotropium and related respiratory maintenance drugs as part of broader multi-source pharmaceutical contracting programs that serve correctional facilities, public health departments, state hospitals, and other government-operated healthcare settings. The solicitations under this code typically flow through cooperative purchasing alliances and state pharmaceutical procurement offices rather than individual agencies, reflecting the standardized contracting and pricing frameworks these entities employ to manage drug supply chains and ensure continuity of care across participating jurisdictions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local facilities, including Oregon. The MMCAP procurement requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and mandates compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing for the contract term, and remaining points on administrative compliance, EDI capability, and administrative-fee agreement. Awarded vendors will be provided to authorized wholesalers by May 15, 2026, with resulting agreements effective July 1, 2026, and the contract term runs two years for new responders with optional extensions at MMCAP's sole discretion. Vendors must maintain comprehensive insurance coverage including $5,000,000 commercial general liability per occurrence and accept a 3 percent administrative fee on all contract purchases.